MA50634A - Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam - Google Patents

Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam

Info

Publication number
MA50634A
MA50634A MA050634A MA50634A MA50634A MA 50634 A MA50634 A MA 50634A MA 050634 A MA050634 A MA 050634A MA 50634 A MA50634 A MA 50634A MA 50634 A MA50634 A MA 50634A
Authority
MA
Morocco
Prior art keywords
sustained
pharmaceutical compositions
compositions containing
release pharmaceutical
containing levetiracetam
Prior art date
Application number
MA050634A
Other languages
English (en)
Inventor
Michela Gallagher
Jack Lawrence James
Elsie Melsopp
Kenneth Garry Payie
Sharon Rosenzweig-Lipson
Original Assignee
Agenebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenebio Inc filed Critical Agenebio Inc
Publication of MA50634A publication Critical patent/MA50634A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA050634A 2015-05-22 2016-05-20 Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam MA50634A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562165812P 2015-05-22 2015-05-22

Publications (1)

Publication Number Publication Date
MA50634A true MA50634A (fr) 2021-04-28

Family

ID=61223552

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050634A MA50634A (fr) 2015-05-22 2016-05-20 Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam

Country Status (4)

Country Link
EP (2) EP3297611B1 (fr)
DK (1) DK3297611T3 (fr)
ES (1) ES2747993T3 (fr)
MA (1) MA50634A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL316051A (en) * 2022-04-01 2024-11-01 Agenebio Inc Methods for preventing or slowing the progression of cognitive decline or impairment in subjects displaying normal cognitive performance

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005398A (es) 2002-11-22 2006-03-09 Univ Johns Hopkins Meta para terapia de deterioro cognitivo.
EP1924712B1 (fr) 2005-08-03 2018-10-03 The Johns Hopkins University Méthodes permettant de caractériser et de traiter un trouble cognitif dû au vieillissement ou à une maladie
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2008062446A2 (fr) * 2006-09-14 2008-05-29 Alembic Limited Composition de lévétiracétam à libération prolongée n'impliquant pas d'effets indésirables en présence d'aliments
EP2346500B1 (fr) * 2008-10-16 2017-05-17 The Johns Hopkins University Procédés et compositions pour l amélioration d'une fonction cognitive
KR20120055313A (ko) * 2010-11-23 2012-05-31 주식회사 바이오파마티스 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법
DE102011103270A1 (de) * 2011-05-26 2012-11-29 Stada Arzneimittel Ag Pulverförmige Mischung zur Herstellung von Levetiracetam-haltigen Tabletten
CA2904767C (fr) * 2013-03-15 2022-06-21 Agenebio, Inc. Procedes et compositions pour ameliorer la fonction cognitive

Also Published As

Publication number Publication date
DK3297611T3 (da) 2019-09-02
ES2747993T3 (es) 2020-03-12
EP3297611A1 (fr) 2018-03-28
EP3590506A1 (fr) 2020-01-08
ES2747993T8 (es) 2021-03-30
EP3297611B1 (fr) 2019-07-03

Similar Documents

Publication Publication Date Title
EP3493799A4 (fr) Composition pharmaceutique decannabis
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3655017T3 (da) Farmaceutisk sammensætning
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
EP3493798A4 (fr) Composition pharmaceutique decannabis
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
DK3529240T3 (da) Farmaceutiske forbindelser
EP3310439A4 (fr) Compositions pharmaceutiques pour des applications anesthésiologiques
MA44212A (fr) Prégabaline à libération prolongée contrôlée
EP3603642A4 (fr) Préparation pharmaceutique
DK3583943T3 (da) Farmaceutisk sammensætning
EP3360547A4 (fr) Composition pharmaceutique bactéricide et virucide
MA49837A (fr) Compositions pharmaceutiques
EP3272362A4 (fr) Composition pharmaceutique à libération prolongée
MA44079A (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
DK3908321T3 (da) Farmaceutisk sammensætning
DK3728220T3 (da) Farmaceutiske forbindelser
EP3705122A4 (fr) Composition pharmaceutique à libération prolongée
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
EP3638211A4 (fr) Compositions pharmaceutiques à libération prolongée retardée
SMT202400478T1 (it) Composizione farmaceutica
EP3646863A4 (fr) Composition pharmaceutique
EP3524250A4 (fr) Composition pharmaceutique
DK3288933T3 (da) Oxindolforbindelser og farmaceutiske sammensætninger deraf
DK3302483T3 (da) Farmaceutiske sammensætninger og anvendelse deraf